CliffBio
small molecule

MOTPOLY XR

LACOSAMIDE

Loss of exclusivityJune 2040latest FDA-listed patent expiry
CompanyAUCTA →View the full company profile on CliffBio

Drug detail

Brand nameMOTPOLY XR
Active ingredientLACOSAMIDE
Strength200MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

Listed patents

PatentExpiresType
11337943June 2040product
12042474June 2040product
11883374June 2040product

More from AUCTA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MOTPOLY XR patent cliff — loss of exclusivity June 2040 | CliffBio